濱江集團(002244.SZ):今年1-3月累計新增借款97.67億元
格隆匯4月6日丨濱江集團(002244.SZ)公佈,截至2021年12月31日,公司未經審計的借款餘額為454.36億元,截至2022年3月31日,公司借款餘額為552.03億元(未經審計),公司當年累計新增借款額為97.67億元,佔2021年末公司未經審計淨資產373.64億元的26.14%。
上述新增借款屬於公司正常經營活動範圍。截至公吿出具日,公司經營穩健、盈利情況良好,各項業務經營情況正常。公司將根據已發行的債券和其他債務的本息到期情況,合理調度分配資金,保證按期支付到期利息和本金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.